The value of systemically administered chloroquine and other antimalarial compounds in lupus erythematosus, polymorphic light eruptions, and other cutaneous disorders is extensively documented and well established.1-4 The chemicophysiological mechanisms involved in the resulting beneficial effects are not clear in spite of relatively extensive investigation.5 Numerous side-effects of antimalarial administration are well catalogued, and these include vertigo, headache, nausea, visual disturbances, pigmentary and other abnormalities.6 The degree and incidence of these undesirable effects are frequently dependent upon the level of dosage, so that in some instances therapeutically desirable levels can not be achieved and/or maintained because of these effects. In an attempt to attain high tissue levels in cutaneous lesions without systemic reactions, a study of intradermal injection of chloroquine* has been in progress for the past 9 months. Results in 3 typical patients follow.
Chloroquine dihydrochloride solution, 50 mg. per cu. cm. in 3 cc. ampules,
EVERETT MA, COFFEY CM. Intradermal Administration of Chloroquine: For Discoid Lupus Erythematosus and Lichen Sclerosus et Atrophicus. Arch Dermatol. 1961;83(6):977–979. doi:10.1001/archderm.1961.01580120089022
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: